Reports net product revenue $11.5M vs. $11.7M last year. Mytesi prescription volume decreased approximately 3.7% in the year 2025 over 2024, by approximately 5.8% in the fourth quarter of 2025 over the third quarter of 2025, and by approximately 12.2% in the fourth quarter of 2025 over the fourth quarter of 2024. Prescription volume differs from invoiced sales volume, which reflects, among other factors, varying buying patterns among specialty pharmacies in the closed network as they manage their inventory levels.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health Delays Annual Form 10-K Filing
- Psychedelic: AtaiBeckley reports publication of BPL-003 study results
- Jaguar Health announces FDA support for Napo’s protocol amendment
- Magdalena initiates preclinical study of coca for appetite suppression
- Jaguar Animal Health Restructures Debt and Royalty Agreements